CC
Casdin Capital Portfolio holdings
AUM
$1.1B
1-Year Return
24.98%
This Quarter Return
+14.38%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$814M
AUM Growth
+$106M
(+15%)
Cap. Flow
+$81M
Cap. Flow
% of AUM
9.95%
Top 10 Holdings %
Top 10 Hldgs %
56.48%
Holding
38
New
4
Increased
14
Reduced
3
Closed
2
Top Buys
| 1 |
NVTA
Invitae Corporation
NVTA
|
+$40.2M |
| 2 |
BioLife Solutions
BLFS
|
+$25M |
| 3 |
Agios Pharmaceuticals
AGIO
|
+$16.6M |
| 4 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$11.6M |
| 5 |
GRTS
Gritstone bio, Inc. Common Stock
GRTS
|
+$10.3M |
Top Sells
| 1 |
FMI
Foundation Medicine, Inc.
FMI
|
+$93.6M |
| 2 |
Zai Lab
ZLAB
|
+$3.14M |
| 3 |
OraSure Technologies
OSUR
|
+$1.78M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$1.52M |
| 5 |
Fate Therapeutics
FATE
|
+$815K |
Sector Composition
| 1 | Healthcare | 87.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
OraSure Technologies
OSUR
$238M
| $8.11M | 0.99% |
525,000
-115,000
| -18% | -$1.78M |
|
27
Q32 Bio
QTTB
$20.4M
| $8M | 0.97% |
19,444
+13,055
| +204% | +$5.37M |
|
|
CLVS
28
DELISTED
Clovis Oncology, Inc.
CLVS
| $6.9M | 0.84% |
235,000
+15,000
| +7% | +$441K |
|
29
Sarepta Therapeutics
SRPT
$1.84B
| $6.46M | 0.79% |
+40,000
| New | +$6.46M |
|
30
CareDx
CDNA
$710M
| $5.77M | 0.7% |
200,000
| – | – |
|
31
Neogen
NEOG
$1.23B
| $4.65M | 0.57% |
130,000
| – | – |
|
32
CytomX Therapeutics
CTMX
$360M
| $3.84M | 0.47% |
207,500
| – | – |
|
|
NTGN
33
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
| $2.89M | 0.35% |
338,345
| – | – |
|
|
JNCE
34
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $2.44M | 0.3% |
375,000
| – | – |
|
35
Gilead Sciences
GILD
$144B
| – | – |
0
| – | – |
|
|
36
Zai Lab
ZLAB
$3.49B
| – | – |
-135,000
| Closed | -$3.14M |
|
|
FMI
37
DELISTED
Foundation Medicine, Inc.
FMI
| – | – |
-685,000
| Closed | -$93.6M |
|
|
CELG
38
DELISTED
Celgene Corp
CELG
| – | – |
0
| – | – |
|